The Centre for Biomedical Network Research on Rare Diseases (CIBERER) was created in 2006 in order to act as a reference, coordinate and foster research on rare diseases in Spain.
It is one of the nine consortiums with own legal personality and dependent upon the Instituto de Salud Carlos III (ISCIII) – Ministry of Economy and Competitiveness, within its plan to create stable Cooperative Research structures in the field of biomedicine.
The CIBER on Rare Diseases or CIBERER is a centre orientated towards the development and implementation of cooperative research in the field of rare diseases, favouring basic, clinical and epidemiological biomedical research, placing special emphasis on transferring the research from the laboratory to the patient’s bedside and scientifically responding to the questions that arise from the interaction between physician and patient.
The Centre has an innovative structure, which is based on the trajectory and research potential of the research groups that form part of it. The Consortium provides strategic coordination, human and material resources, as well as a collaborative environment to be able to exploit the specific synergies of the great potential of multidisciplinary and complementary knowledge. The groups are integrated into scientific programmes where these collaborations are coordinated and favoured.
CIBERER is a public state centre exclusively devoted to research into rare diseases, combining a strong basic and translational component. It has 60 clinical and basic research groups, belonging to 29 Spanish benchmark research institutions, distributed in 8 Autonomous Communities, and it maintains many Collaboration Agreements with different public and private centres. More than 700 hired and attached scientists and researchers comprise its human team. The research activities of CIBERER are organised into seven Research Programmes (PdI) established according to different medical themes. We can mention the following scientific research fields of interest for CIBERER, among others: integrated biological research into rare diseases and associated physiopathological processes; monogenic diseases, metabolic routes and new potential therapeutic targets; functional, proteomic and biocomputing genomics; pharmacogenetics and pharmacogenomics; development of animal and cellular models of rare diseases; systems biology in rare diseases; clinical and genetic epidemiology of populations; and research into rare and genetic disease health services.